

#14

0300

Please place a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)



Application Number	09/845,786
Filing Date	April 30, 2001
First Named Inventor	Svetlana Doronina
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	840065.425

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 (3 Sheets) <input checked="" type="checkbox"/> 35 Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____ _____
---	---	---


Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	David W. Parker	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	July 11, 2001	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name	SHARIE F. Lambing	
Signature		Date: 7/11/01



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Svetlana Doronina et al.
Application No. : 09/845,786
Filed : April 30, 2001
For : PENTAPEPTIDE COMPOUNDS AND USES RELATED
THERE TO

Docket No. : 840065.425
Date : July 11, 2001

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached forms PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

A handwritten signature in black ink, appearing to read "David W. Parker", written over a horizontal line.

David W. Parker

Registration No. 37,414

DWP:sfl

Enclosures:

PTO/SB/21

Postcard

Forms PTO-1449 (3 Sheets)

Cited References (35)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\NrPortbl\iManage\SHANEL\193703_1.DOC

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 840065.425	APPLICATION NO. 09/845,786
INFORMATION DISCLOSURE STATEMENT (Use for Trademarks if necessary)		APPLICANTS Svetlana Doronina et al.	
		FILING DATE April 30, 2001	GROUP ART UNIT Not yet assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	5,741,892	04/21/98	Barlozzari et al.	530	330	
	BB	5,767,237	06/16/98	Sakakibara et al.	530	330	
	BC	5,780,588	07/14/98	Pettit et al.	530	330	
	BD	5,840,699	11/24/98	Sakakibara et al.	514	18	
	BE	6,004,934	12/21/99	Sakakibara et al.	514	18	
	BF	6,034,065	03/07/00	Pettit et al.	514	18	
	BG	6,124,431	09/26/00	Sakakibara et al.	530	331	
	BH	6,162,930	12/19/00	Pinney et al.	549	57	

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BI					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BJ	Pettit et al., "Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications," <i>Anti-cancer Drug Des</i> 10(7):529-544, October 1995.
	BK	Pettit et al., "The Dolastatins. 17. Synthesis of Dolaproine and Related Diastereoisomers," <i>J. Organic Chemistry</i> 59(21):6287-6295, 1994.
	BL	Pettit et al., "The Dolastatins; 18: Stereospecific Synthesis of Dolaproine," <i>Synthesis</i> 6:719-725, June 1996.
	BM	Pettit et al., "The Dolastatins. 19. Synthesis of Dolaisoleuine," <i>J. Organic Chemistry</i> 59(7):1796-1800, 1994.
	BN	Pettit et al., "The Dolastatins. 23: Stereospecific Synthesis of Dolaisoleuine," <i>J. Chem. Soc., Perkin Trans. 1</i> :853-858, 1996.
	BO	Pettit et al., "The Dolastatins 24. Synthesis of (-)-dolastatin 10. X-Ray Molecular Structure of <i>N,N</i> -Dimethylvalyl-valyl-dolaisoleuine, <i>tert</i> -Butyl Ester," <i>J. Chem. Soc., Perkin Trans. 1</i> :859-863, 1996.
	BP	Pettit, <i>The Dolastatins</i> (reprint), Springer-Verlag, New York, 1997, pages 1-79

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 840065.425	APPLICATION NO. 09/845,786
 <p>INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)</p>		APPLICANTS Svetlana Doronina et al.	
		FILING DATE April 30, 2001	GROUP ART UNIT Not yet assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CK					
	CL					
	CM					
	CN					
	CO					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CP	Shioiri et al., "Stereoselective Synthesis of Dolastatin 10 and Its Congeners," <i>Tetrahedron</i> 49(9):1913-1924, 1993.
	CQ	Tomioka et al., "An Expeditious Synthesis of Dolastatin 10," <i>Tetrahedron Letters</i> 32(21):2395-2398, 1991.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 840065.425		APPLICATION NO. 09/845,786	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Svetlana Doronina et al.		FILING DATE April 30, 2001	
				GROUP ART UNIT Not yet assigned			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,414,205	11/08/83	Pettit	424	177	
	AB	4,816,444	03/28/89	Pettit et al.	514	17	
	AC	4,879,278	11/07/89	Pettit et al.	514	17	
	AD	4,978,744	12/18/90	Pettit et al.	530	330	
	AE	5,410,024	04/25/95	Pettit et al.	530	330	
	AF	5,521,284	05/28/96	Pettit et al.	530	330	
	AG	5,530,097	06/25/96	Pettit et al.	530	330	
	AH	5,554,725	09/10/96	Pettit	530	330	
	AI	5,599,902	02/04/97	Pettit et al.	530	330	
	AJ	5,635,483	06/03/97	Pettit et al.	514	17	
	AK	5,654,399	08/05/97	Sakakibara et al.	530	330	
	AL	5,663,149	09/02/97	Pettit et al.	514	17	
	AM	5,665,860	09/09/97	Pettit et al.	530	330	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	AN	EP 598 129 A1	05/25/94	EPO			
	AO	WO 01/18032	03/15/01	WIPO			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AP	Bowman and Stroud., "N-Substituted Amino-acids. Part I. A New Method of Preparation of Dimethylamino-acids," <i>J. Chem. Soc.</i> , pages 1342-1344, 1950.					
	AQ	Miyazaki et al., "Synthesis and Antitumor Activity of Novel Dolastatin 10 Analogs," <i>Chem. Pharm. Bull.</i> 43(10):1706-1718, October 1995.					
	AR	Pettit et al., "Antineoplastic Agents 365. Dolastatin 10 SAR Probes," <i>Anti-Cancer Drug Design</i> 13:243-277, 1998.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							